{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:38:32Z","timestamp":1791873512318,"version":"4.3.4"},"reference-count":109,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/01\/X\/NZ2\/01906"],"award-info":[{"award-number":["2017\/01\/X\/NZ2\/01906"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Polish Ministry of Science and Higher Education","award":["SPUB 5536\/E-63\/SPUB\/2017\/1"],"award-info":[{"award-number":["SPUB 5536\/E-63\/SPUB\/2017\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The expression of apoptosis-related BCL2 family genes, fine-tuned in normal cells, is dysregulated in many neoplasms. In acute myeloid leukemia (AML), this problem has not been studied comprehensively. To address this issue, RNA-seq data were used to analyze the expression of 26 BCL2 family members in 27 AML FAB M1 and M2 patients, divided into subgroups differently responding to chemotherapy. A correlation analysis, analysis of variance, and Kaplan-Meier analysis were applied to associate the expression of particular genes with other gene expression, clinical features, and the presence of mutations detected by exome sequencing. The expression of BCL2 family genes was dysregulated in AML, as compared to healthy controls. An upregulation of anti-apoptotic and downregulation of pro-apoptotic genes was observed, though only a decrease in BMF, BNIP1, and HRK was statistically significant. In a group of patients resistant to chemotherapy, overexpression of BCL2L1 was manifested. In agreement with the literature data, our results reveal that BCL2L1 is one of the key players in apoptosis regulation in different types of tumors. An exome sequencing data analysis indicates that BCL2 family genes are not mutated in AML, but their expression is correlated with the mutational status of other genes, including those recurrently mutated in AML and splicing-related. High levels of some BCL2 family members, in particular BIK and BCL2L13, were associated with poor outcome.<\/jats:p>","DOI":"10.3390\/cancers13133175","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:07:40Z","timestamp":1624619260000},"page":"3175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9803-6877","authenticated-orcid":false,"given":"Luiza","family":"Handschuh","sequence":"first","affiliation":[{"name":"Laboratory of Genomics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Wojciechowski","sequence":"additional","affiliation":[{"name":"Laboratory of Genomics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland"},{"name":"Institute of Computing Science, Poznan University of Technology, 60-965 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kazmierczak","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60-569 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-2020","authenticated-orcid":false,"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60-569 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: A comprehensive review and 2016 update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: Epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"(2013). Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/7239206","article-title":"Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies","volume":"2019","author":"Handschuh","year":"2019","journal-title":"J. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0065-230X(08)60098-6","article-title":"Functional Aspects of Apoptosis in Hematopoiesis and Consequences of Failure","volume":"71","author":"McKenna","year":"1997","journal-title":"Adv. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2004-07-2761","article-title":"Apoptosis-based therapies for hematologic malignancies","volume":"106","author":"Reed","year":"2005","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1038\/onc.2008.307","article-title":"Bcl-2 family proteins and cancer","volume":"27","author":"Yip","year":"2008","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1515\/bmc-2016-0015","article-title":"Bcl-2 family proteins: Master regulators of cell survival","volume":"7","author":"Hatok","year":"2016","journal-title":"Biomol. Concepts"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: Changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"a008722","DOI":"10.1101\/cshperspect.a008722","article-title":"Multiple Functions of BCL-2 Family Proteins","volume":"5","author":"Hardwick","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Risberg, K., Redalen, K.R., S\u00f8nstevold, L., Bj\u00f8rnetr\u00f8, T., S\u00f8lvernes, J., and Ree, A.H. (2016). Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2600-y"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00018-004-4001-7","article-title":"Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications","volume":"61","author":"Akgul","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1038\/sj.onc.1202591","article-title":"Bcl-2 family proteins","volume":"17","author":"Reed","year":"1998","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fcell.2018.00013","article-title":"Subcellular Localization and Dynamics of the Bcl-2 Family of Proteins","volume":"6","author":"Popgeorgiev","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3538","article-title":"Decoding and unlocking the BCL-2 dependency of cancer cells","volume":"13","author":"Juin","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"key":"ref_25","first-page":"98","article-title":"Bcl-2 oncoprotein expression in acute myeloid leukemia","volume":"80","author":"Bensi","year":"1995","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/sj.leu.2400854","article-title":"High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate","volume":"11","author":"Lauria","year":"1997","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13000-019-0841-1","article-title":"BCL2 overexpression: Clinical implication and biological insights in acute myeloid leukemia","volume":"14","author":"Zhou","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"180002","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_30","first-page":"411","article-title":"Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia","volume":"61","author":"Malpas","year":"1974","journal-title":"Bull. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2012.10.005","article-title":"A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3","volume":"50","author":"Lichtman","year":"2013","journal-title":"Blood Cells. Mol. Dis."},{"key":"ref_32","unstructured":"(1973). Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine. Recent Results Cancer Res. Fortschritte Krebsforsch. Progres Dans Rech. Sur Cancer, 43, 165\u2013168."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2010-05-260117","article-title":"How I treat acute myeloid leukemia","volume":"116","author":"Rowe","year":"2010","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.beha.2019.101094","article-title":"Will new agents impact survival in AML?","volume":"32","author":"Rowe","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_36","first-page":"2690","article-title":"Splicing machinery genomics events in acute myeloid leukaemia (AML): In search for therapeutic targets, diagnostic and prognostic biomarkers","volume":"10","author":"Dlamini","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","article-title":"Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML","volume":"130","author":"Wei","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target. Oncol."},{"key":"ref_43","first-page":"656","article-title":"Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR","volume":"52","author":"Handschuh","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12967-018-1608-2","article-title":"NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome","volume":"16","author":"Handschuh","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Estey","year":"2010","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2004.05285.x","article-title":"Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies","volume":"128","author":"Boogaerts","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.blre.2018.03.006","article-title":"Time to repeal and replace response criteria for acute myeloid leukemia?","volume":"32","author":"Bloomfield","year":"2018","journal-title":"Blood Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Li, B., and Dewey, C.N. (2011). RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12.","DOI":"10.1186\/1471-2105-12-323"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biocel.2019.02.007","article-title":"The landscape of chimeric RNAs in bladder urothelial carcinoma","volume":"110","author":"Zhu","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Brown","year":"2007","journal-title":"J. Clin. Invest."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(93)90508-N","article-title":"bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death","volume":"74","author":"Boise","year":"1993","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"32875","DOI":"10.1074\/jbc.C112.366559","article-title":"The Transcription Factor Wilms Tumor 1 Confers Resistance in Myeloid Leukemia Cells against the Proapoptotic Therapeutic Agent TRAIL (Tumor Necrosis Factor \u03b1-related Apoptosis-inducing Ligand) by Regulating the Antiapoptotic Protein Bcl-xL","volume":"287","author":"Bansal","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1385\/IR:22:2-3:83","article-title":"The Role of Apoptosis in Regulating Hematopoiesis and Hematopoietic Stem Cells","volume":"22","author":"Domen","year":"2000","journal-title":"Immunol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lin, J.-C., Tsao, M.-F., and Lin, Y.-J. (2016). Differential Impacts of Alternative Splicing Networks on Apoptosis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122097"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.iy.13.040195.002501","article-title":"Regulation of Lymphocyte Survival by the BCL-2 Gene Family","volume":"13","author":"Cory","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e2345","DOI":"10.1038\/cddis.2016.237","article-title":"MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL","volume":"7","author":"Slomp","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1073\/pnas.86.6.1958","article-title":"Overexpression of the human BCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells","volume":"86","author":"Tsujimoto","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0092-8674(93)90462-Y","article-title":"Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors","volume":"74","author":"Fairbairn","year":"1993","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood.V92.9.3226","article-title":"Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage","volume":"92","author":"Zhou","year":"1998","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2141.1994.tb04984.x","article-title":"The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia","volume":"88","author":"Maung","year":"1994","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0609.1999.tb01112.x","article-title":"Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia","volume":"62","author":"Bincolettu","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1365-2141.2003.04121.x","article-title":"Abnormal expression of apoptosis-related genes in haematological malignancies: Overexpression of MYC is poor prognostic sign in mantle cell lymphoma","volume":"120","author":"Nagy","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1242\/jcs.115.8.1567","article-title":"BH3-only proteins\u2014Evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death","volume":"115","author":"Bouillet","year":"2002","journal-title":"J. Cell Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.leu.2400705","article-title":"Bcl-xL is heterogeneously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression","volume":"11","author":"Pallis","year":"1997","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41375-019-0611-9","article-title":"Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma","volume":"34","author":"Adams","year":"2020","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004030050479","article-title":"Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma","volume":"292","author":"Leiter","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/gyno.1998.5125","article-title":"Bcl-xLIs Expressed in Ovarian Carcinoma and Modulates Chemotherapy-Induced Apoptosis","volume":"70","author":"Liu","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/B:BREA.0000041579.51902.89","article-title":"Overexpression of Bcl-xL in Human Breast Cancer Cells Enhances Organ-Selective Lymph Node Metastasis","volume":"87","author":"Rubio","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1210\/en.2006-0502","article-title":"Bcl-xL Is Overexpressed in Hormone-Resistant Prostate Cancer and Promotes Survival of LNCaP Cells via Interaction with Proapoptotic Bak","volume":"147","author":"Castilla","year":"2006","journal-title":"Endocrinology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41419-020-03092-7","article-title":"Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer","volume":"11","author":"Scherr","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/febs.13188","article-title":"Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: Implications for targeted therapy","volume":"282","author":"Sochalska","year":"2015","journal-title":"FEBS J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1101\/gad.14.1.23","article-title":"Mcl-1 deficiency results in peri-implantation embryonic lethality","volume":"14","author":"Rinkenberger","year":"2000","journal-title":"Genes Dev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cdd.2011.158","article-title":"BCL2A1: The underdog in the BCL2 family","volume":"19","author":"Vogler","year":"2012","journal-title":"Cell Death Differ."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.10030","article-title":"Mutation of bcl-x gene in non-Hodgkin\u2019s lymphoma","volume":"69","author":"Yamaguchi","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"12492","DOI":"10.1073\/pnas.1507491112","article-title":"Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer","volume":"112","author":"Park","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/carcin\/bgh145","article-title":"Inactivating mutations of proapoptotic Bad gene in human colon cancers","volume":"25","author":"Lee","year":"2004","journal-title":"Carcinogenesis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2016.06.001","article-title":"Functional Implications of the spectrum of BCL2 mutations in Lymphoma","volume":"769","author":"Singh","year":"2016","journal-title":"Mutat. Res. Mutat. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Bilbao-Sieyro, C., Rodr\u00edguez-Medina, C., Florido, Y., Stuckey, R., S\u00e1ez, M.N., S\u00e1nchez-Sosa, S., Gonz\u00e1lez Mart\u00edn, J.M., Santana, G., Gonz\u00e1lez-P\u00e9rez, E., and Cruz-Cruz, N. (2020). BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia. Diagnostics, 10.","DOI":"10.3390\/diagnostics10121048"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1940-6207.CAPR-12-0105","article-title":"Determination of Molecular Markers for BRCA1 and BRCA2 Heterozygosity Using Gene Expression Profiling","volume":"6","author":"Salmon","year":"2013","journal-title":"Cancer Prev. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1074\/mcp.M700590-MCP200","article-title":"Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis","volume":"7","author":"Thorsen","year":"2008","journal-title":"Mol. Cell. Proteom."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.1973010","article-title":"Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged","volume":"24","author":"David","year":"2010","journal-title":"Genes Dev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1158\/1078-0432.CCR-13-0956","article-title":"A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets","volume":"20","author":"Adamia","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cell.2010.07.019","article-title":"An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis","volume":"142","author":"Moore","year":"2010","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V120.21.406.406","article-title":"SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and \u226515% Ring Sideroblasts and Are Closely Related to FLT3-ITD and RUNX1 Mutations","volume":"120","author":"Jeromin","year":"2012","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood.V128.22.1976.1976","article-title":"SF3B1 Mutations in AML, MDS and MDS\/MPN-RS-T Are Accompanied By Different Other Gene Mutations: Impact for Targeted Treatment Studies","volume":"128","author":"Meggendorfer","year":"2016","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-020-0839-4","article-title":"Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia","volume":"34","author":"Bamopoulos","year":"2020","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1016\/j.jprot.2012.07.030","article-title":"Comparative proteome analysis of acute myeloid leukemia with and without maturation","volume":"75","author":"Luczak","year":"2012","journal-title":"J. Proteom."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cell.2011.02.034","article-title":"Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol","volume":"145","author":"Edlich","year":"2011","journal-title":"Cell"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Fiebig, A.A., Zhu, W., Hollerbach, C., Leber, B., and Andrews, D.W. (2006). Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer, 6.","DOI":"10.1186\/1471-2407-6-213"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.leu.2404719","article-title":"ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells","volume":"21","author":"Kline","year":"2007","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008255511404","article-title":"High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia","volume":"9","author":"Karakas","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.leu.2402434","article-title":"The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia","volume":"16","author":"Karakas","year":"2002","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2002-06-1714","article-title":"Amount of spontaneous apoptosis detected by Bax\/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)","volume":"101","author":"Venditti","year":"2003","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"De haes, I., Dendooven, A., Mercier, M.L., Puylaert, P., Vermeulen, K., Kockx, M., Deiteren, K., Maes, M.-B., Berneman, Z., and Anguille, S. (2020). Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103090"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","article-title":"Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid","volume":"13","author":"Andreeff","year":"1999","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:04Z","timestamp":1760163844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":109,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13133175"],"URL":"https:\/\/doi.org\/10.3390\/cancers13133175","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}